-
CLINICAL TRIAL EVIDENCE SUPPORTING FDA APPROVAL OF NOVEL AGENTS IN 2024
Feb 25, 2026, 14:43 PM -
FROM REAL-WORLD DATA (RWD) TO DIGITAL TWINS: BUILDING MODELS FOR PATIENT-LEVEL COUNTERFACTUAL PREDICTION IN ONCOLOGY
Feb 25, 2026, 14:43 PM -
EMPIRICAL TIME-SERIES ANALYSES IN THE PAST THREE DECADES 1991-2023 FOR IMMUNE THROMBOCYTOPENIA MEDICATIONS IN THE US MEDICAID PROGRAMS
Feb 25, 2026, 14:43 PM -
COST-EFFECTIVENESS OF ROBOTIC-ASSISTED VERSUS LAPAROSCOPIC SURGERY FOR MID-LOW RECTAL CANCER: EVIDENCE FROM A MULTICENTER RANDOMIZED TRIAL IN CHINA
Feb 25, 2026, 14:43 PM -
COMPARING THECOSTEFFECTIVENESS OFONSITEBUPRENORPHINE TREATMENT VERSUSTREATMENT FACILITY REFERRALATHARM REDUCTION AGENCIES
Feb 25, 2026, 14:43 PM -
ECONOMIC EVALUATION OF HORMONAL TREATMENT STRATEGIES FOR INFANTILE EPILEPTIC SPASMS SYNDROME IN INDIAN CHILDREN
Feb 25, 2026, 14:43 PM -
REAL-WORLD EVIDENCE CHALLENGING THE THERAPY-DEPENDENT RISK PARADIGM FOR THERAPY-RELATED AML IN HEAD AND NECK CANCER SURVIVORS
Feb 25, 2026, 14:43 PM -
FLARE FREQUENCY, ORGAN DAMAGE, AND ECONOMIC BURDEN AMONG INDIVIDUALS WITH IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD) IN THE UNITED STATES
Feb 25, 2026, 14:43 PM -
ADVANCING EQUITY IN PROSTATE CANCER RESEARCH: STRATEGY AND OUTCOMES FROM A PROSPECTIVE ENROLLMENT INITIATIVE
Feb 25, 2026, 14:43 PM -
EFFECTIVENESS OF A VIDEO-BASED TELEREHABILITATION FOR FALL PREVENTION IN OLDER ADULTS
Feb 25, 2026, 14:43 PM -
US MEDICINE PRICING POLICY CHANGES: IMPACT ON THE FULL BIOPHARMACEUTICAL INVESTMENT ECOSYSTEM
Feb 25, 2026, 14:43 PM -
ASSESSING THE IMPACT OF MISSINGNESS IN TREATMENT EFFECT MODIFIERS ON BIAS IN ANCHORED AND UNANCHORED MAIC AND STC
Feb 25, 2026, 14:43 PM -
COST ANALYSIS OF WHOLE-BODY PET-CT SCAN USING TIME-DRIVEN ACTIVITY-BASED COSTING AT A GOVERNMENT CANCER HOSPITAL IN NORTH INDIA
Feb 25, 2026, 14:43 PM -
OUT-OF-POCKET COST BURDEN AMONG PATIENTS DIAGNOSED WITH BREAST CANCER AND MENTAL HEALTH COMORBIDITIES: A CROSS-SECTIONAL STUDY USING MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA
Feb 25, 2026, 14:43 PM -
AI-ASSISTED APPROACHES FOR DEFINING LINES OF THERAPY IN ONCOLOGY REAL-WORLD DATA: AN EXPLORATORY ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA
Feb 25, 2026, 14:43 PM -
HEALTH EQUITY IMPACT OF ACADEMIC DETAILING ON NALOXONE DISTRIBUTION IN THE UNITED STATES: AN AGGREGATE DISTRIBUTIONAL COST-EFFECTIVENESS ANALYSIS
Feb 25, 2026, 14:43 PM -
COST-EFFECTIVENESS OF FITUSIRAN PROPHYLAXIS VERSUS FACTOR VIII ON-DEMAND OR PROPHYLACTIC THERAPY FOR HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
Feb 25, 2026, 14:43 PM -
CAN PUBMED ALONE CAPTURE THE EVIDENCE BASE FOR TARGETED LITERATURE REVIEWS? A CASE STUDY
Feb 25, 2026, 14:43 PM -
HEALTHCARE RESOURCE UTILIZATION AND COSTS OF DIABETES MELLITUS: A RETROSPECTIVE REAL-WORLD COST-OF-ILLNESS ANALYSIS IN BRAZIL
Feb 25, 2026, 14:43 PM -
COULD OPERATING-ROOM TIME DIFFERENCES FOR LITHOTRIPSY BE AN INDICATOR OF HEALTHCARE ACCESS?
Feb 25, 2026, 14:43 PM
